Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim

Open Access
Publisher Website
Google Scholar
Abstract
This study assessed the ability of recombinant human stem cell factor (rHuSCF) to mobilize stem cells in 44 patients who had failed a prior mobilization (CD34+ yield 0.5–1.9 × 106/kg BW) with filgrastim-alone or chemotherapy-plus-filgrastim. The same mobilization regimen was used with the addition of rHuSCF. In the filgrastim-alone group (n=13), rHuSCF 20 μg/kg was started 3 days before filgrastim and continued for the duration of filgrastim. In the chemotherapy-plus-filgrastim group (n=31), rHuSCF 20 μg/kg/day plus filgrastim 5–10 μg/kg/day were administered concurrently. Leukaphereses were continued to a maximum of four procedures or a target of ⩾ 3 × 106 CD34+ cells/kg. In both groups, CD34+ yield (× 106/kg BW) of the study mobilization was higher than that of the prior mobilization (median: 2.42 vs 0.84 P=0.002 and 1.64 vs 0.99 P=6/kg. The probability of a successful mobilization was the same in those with a CD34+ yield of 0.5–0.75 × 106/kg BW in the prior mobilization as in those with 0.76–1.99 × 106/kg BW. Downmodulation of c-kit expression and a lower percentage of Thy-1 positivity in the mobilized CD34+ cells were noted in the successful mobilizers compared with those in the poor mobilizers. This study shows that rhuSCF is effective in approximately half the patients who had failed a prior mobilization and allows them to proceed to transplant. It also points to the likely role of the SCF/c-kit ligand pair in mobilization.

This publication has 18 references indexed in Scilit: